Guide 04 · Titration
Titration, Explained
Titration is the schedule of gradual dose increases that every GLP protocol follows. This guide explains why it exists, what it looks like, and why rushing it backfires.
The reason
Why every protocol starts low
GLP medications slow how quickly your stomach empties. That is part of how they quiet appetite, and it is also the reason the first dose of every protocol is small. Your digestive system has run at one speed your whole life; it needs weeks, not days, to adapt to a new one.
Start too high and the adjustment period becomes the whole experience: nausea, an unsettled stomach, food sitting heavier than it should. Start low and step up gradually, and most people find each increase far easier to absorb because the body has already done most of the adapting.
So if the starting dose feels almost symbolic, that is by design. Starting low is about tolerability, not weakness, and it is the same on-ramp the clinical trials themselves used.
The shape of it
What a schedule actually looks like
Start
The first weeks
Every protocol opens at a deliberately low dose. It is not the dose that produces the trial results; it is the dose that lets your digestive system meet the medication gently. Appetite often quiets even here, but the job of this phase is adjustment.
Hold
Sit with each step
Each dose is held for a stretch of weeks, typically about four, before anything changes. Holding is not lost time. It is your body building tolerance so the next step lands softly instead of all at once.
Step up
One rung at a time
When a hold period ends and you are tolerating the dose well, the schedule moves up one step. Repeat until you reach the maintenance dose your protocol targets. That is the entire mechanic; the discipline is in not skipping rungs.
The exact doses and step sizes differ between Semaglutide, Tirzepatide, and Retatrutide, so we do not print one generic ladder here. Every product page in the shop shows its own week-by-week schedule for that specific medication, which is the one to follow.
The long game
Patience is the protocol
The temptation, a few weeks in, is to jump ahead: skip a rung, shorten a hold, get to the higher dose sooner. What that actually buys is the hard part up front. Side effects concentrate around dose increases, so stacking increases together front-loads the nausea without meaningfully pulling the results forward.
The results everyone quotes came from studies built on patience. The landmark trials ran 68 to 80 weeks, well over a year of steady weekly doses, and that is the timeline behind the averages: roughly 15% average body weight lost with Semaglutide in STEP-1, roughly 21% with Tirzepatide in SURMOUNT-1, and roughly 28% with Retatrutide in TRIUMPH-1. Nobody in those studies got there in a month, and nobody was expected to.
Trial averages, not a prediction. These are the average results across participants in each cited clinical trial. Individual results vary and depend on eligibility, adherence, dosing, health factors, nutrition, and activity.
When progress pauses
Plateaus are part of the plan
At some point the scale will hold still for a few weeks. This is normal, it happened inside the trials too, and it is usually not a sign that anything is wrong. Often the next scheduled step in the titration is what moves things again; sometimes the right move is simply holding steady at the current dose and letting time do its work.
If you want to see the shape of the journey before you start, the calculator traces a trial-average curve over 18 months: steep early, flattening later, with long stretches that look like nothing is happening. Seeing that shape in advance makes the quiet weeks much easier to sit through.
As with everything in these guides, this is general research context, not medical advice. Talk to a licensed healthcare professional about your own titration and your own health.
Next up: How to Send an e-Transfer, a screenshot-level walkthrough of paying for an order.